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Abstract
Thirty consecutive Acinetobacter baumannii isolates producing
carbapenem-hydrolysing oxacillinases, OXA-23 or OXA-58,
were recovered from patients hospitalized in Rome, Italy,
between January and November 2007. Among these isolates,
two clones not associated with the European clones I or II were
observed. The oxacillinase-encoding genes were plasmid- or
chromosome-borne. This study reports the dissemination of
carbapenem-resistant A. baumannii belonging to two clones
among several units in a single hospital and emphasizes the
ability of A. baumannii to cause epidemic/endemic outbreaks and
also to acquire various resistance genes circulating in the
hospital environment.
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Acinetobacter baumannii is an opportunistic pathogen present
in healthcare environments, due to its ability to survive in
human skin and dry surfaces to a greater extent than other
hospital-acquired Gram-negative bacilli [1]. This microorgan-
ism produces chromosomally encoded class C and OXA-51/
69-like b-lactamases, with their expression varying according
to the presence of ISAba [2–4]. This genetic background
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may provide intrinsic resistance to narrow- and extended-
spectrum b-lactams [5]. Furthermore, this species can also
readily acquire foreign DNA [6].
These characteristics establish A. baumannii as a successful
nosocomial pathogen that can cause a variety of infections,
frequently associated with immunosuppressed patients with
serious underlying diseases [2]. As such, numerous outbreaks
and escalated antimicrobial resistance rates have been
reported, making carbapenems the agent of choice [6]. How-
ever, the clinical utility of this class has been compromised by
the dissemination of acquired carbapenem-hydrolysing
Ambler class D b-lactamases (CHCDb) [5]. The objective of
this study was to analyse the spread of carbapenem-resistant
A. baumannii recovered from patients hospitalized in different
units of the Polyclinic Agostino Gemelli – Universita` Cattolica
del Sacro Cuore (Rome, Italy). This 2000-bed university hos-
pital is one of the largest and most important medical institu-
tions in Italy, treating more than 70 000 in-patients each year.
As part of the 2007 SENTRY Surveillance, 34 non-repeti-
tive Acinetobacter spp. (one isolate per patient) were submit-
ted to a central monitoring laboratory (JMI Laboratories,
North Liberty, IA, USA).
The isolates were tested for susceptibility by broth micro-
dilution (TREK Diagnostics Inc., Cleveland, OH, USA); testing
and interpretation were performed according to the CLSI
recommendations [7,8]. Tigecycline MIC results were inter-
preted according to the Enterobacteriaceae breakpoints
approved by the US Food and Drug Administration (£2/
‡8 mg/L for susceptible/resistant). Among these isolates, 30
showed resistance to imipenem, penicillins, cephalosporins,
monobactams, b-lactam–b-lactamase inhibitor combinations,
and variable susceptibility to aminoglycosides [amikacin
(78.1% susceptible), gentamicin and tobramycin (19.4%)] and
tetracyclines [tigecycline (93.5%; two intermediate isolates),
minocycline (74.2%) and doxycycline (38.7%)]. Only poly-
myxin B and colistin exhibited 100% susceptibility in vitro.
These isolates were recovered from blood (87.1%) or skin
and soft tissue (12.9%), mostly from patients hospitalized in
intensive care units (60%; Table 1) and many of these
patients were treated with colistin or tigecycline. Among the
remaining Acinetobacter spp. isolated during the study period,
one showed susceptibility to carbapenems and three isolates
were Acinetobacter species other than A. baumannii, according
to PCR-negative results for blaOXA-51/69.
PCR mapping followed by sequencing using primers
speciﬁc for CHCDb and ISAba1, -2 or -3 [3,9] revealed the
presence of blaOXA-23 and blaOXA-58 clusters, and the ISAba1
and ISAba3 were located upstream of the oxacillinase genes,
respectively. This approach allowed sequencing of both genes
and the analysis revealed complete identity with previously
described blaOXA-23 and blaOXA-58 genes. Metallo-b-lactamas-
es (MbL) [10] were not detected among the resistant iso-
lates and neither carbapenamase (CHCDb or MbL) was
detected among the susceptible isolates.
Pulsed-ﬁeld gel electrophoresis (PFGE) with ApaI was
performed to investigate clonality and pattern analysis was
carried out using the GelCompar II software (Applied Math,
Kortrijk, Belgium). Percent similarities were identiﬁed on a
dendrogram derived from the unweighted pair group method
using arithmetic averages and based on Dice coefﬁcients.
Band position tolerance and optimization were set at 1.5%
and 0.5%, respectively, and isolates showing a similarity coef-
ﬁcient ‡87% were considered to be genetically related, as
previously described [11]. The results demonstrated the
presence of two clones (A and B) harbouring either blaOXA-
23 or blaOXA-58, and the imipenem-susceptible A. baumannii
isolated during the study period clustered within clone B
(Fig. 1). Since blaOXA-58 has been associated with carbapenem
resistance in isolates belonging to the pan-European epidemic
clone II [12], we compared the ApaI restriction proﬁles
obtained in this study with the European clones I and II;
however, clones A and B did not match these European
clones (Fig. 1).
Plasmid band sizes were determined with GelCompar II
software using plasmid bands from Escherichia coli NCTC
50192 as a reference standard. Band position tolerance and
optimization were set at 1.0% and 0.5%, respectively.
OXA-23-producing A. baumannii belonging to cluster A dem-
onstrated the presence of four plasmid bands and blaOXA-23-
speciﬁc probe hybridized with the 32-kb plasmid band
(Table 1). Total bacterial DNA of those OXA-23-producing
A. baumannii belonging to cluster A was digested with I-CeuI
and hybridization signals from the 487-kb chromosomal
DNA bands were also observed using a blaOXA-23 and 16S
rRNA probe (data not shown), suggesting that blaOXA-23 was
plasmid- and chromosome-borne in these isolates. One iso-
late belonging to cluster A harboured blaOXA-58, which was
located in the 20-kb plasmid band (Table 1). Among those
A. baumannii belonging to cluster B, two isolates harboured
blaOXA-23 and plasmid preparations showed two plasmid
bands (44 and 27 kb); hybridization signals were obtained
from the 44-kb band. Additionally, ﬁve isolates also belonging
to clone B harboured blaOXA-58 and showed two plasmid
bands (44 and 27 kb), and the oxacillinase gene was located
in the 44-kb plasmid band (Table 1). One OXA-58-producing
strain belonging to clone B (subtype B1) exhibited multiple
plasmid bands and blaOXA-58 hybridization signals were
observed in the 49- and 22-kb bands.
This study describes the dissemination of two complex
carbapenem-resistant A. baumannii clusters among hospital
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units at the Polyclinic Agostino Gemelli. Several studies have
reported the detection of OXA-58-producing A. baumannii in
Italy, suggesting that blaOXA-58-carrying A. baumannii has
become endemic [13–15]; however, reports concerning
blaOXA-23- or blaOXA-24-like genes are limited to the descrip-
tion of two isolates carrying blaOXA-24 and one isolate carry-
ing blaOXA-23, recovered in 2000 from northern Italy [16]
and from the Agostino Gemelli Hospital (Rome) in 2004,
respectively [17]. To our knowledge, this is the ﬁrst report
of hospital dissemination of blaOXA-23-carrying A. baumannii in
Italy. The presence of multiple copies of CHCDb-encoding
genes provides increased levels of resistance among these
clinical isolates [15]. Moreover, although deaths related to
infection rates were very low in this study (3.2%), these ﬁnd-
ings emphasize the ability of A. baumannii isolates to spread
and to acquire different resistance determinants circulating in
the hospital environment.
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Abstract
The present study, comprising a prospective multicentre study
including 53 non-neutropenic patients from intensive care units
(ICU) in six Spanish tertiary-care hospitals, was carried out to
determine the clinical signiﬁcance and inﬂuence on mortality of
Candida albicans germ tube-speciﬁc antibodies (CAGTA). There
were 22 patients (41.5%) for whom the CAGTA results were
positive, although none of had a blood culture positive for
Candida. The intra-ICU mortality rate was signiﬁcantly lower
(p = 0.004) in CAGTA-positive patients (61.2% vs. 22.7%).
Multivariate analysis conﬁrmed that a positive CAGTA result
was the only protective factor to be independently associated
with ICU mortality (b coefﬁcient = )0.3856; 95% conﬁdence
interval = )0.648 to )0.123).
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The mortality rate of invasive candidiasis (IC) remains exces-
sively high [1] and is associated with the difﬁculty of making
a prompt microbiological diagnosis [2] and a delay in antifun-
gal treatment [3,4]. To date, no single serological test has
demonstrated widespread clinical acceptance [5]. An immu-
noﬂuorescence assay (Candida albicans IFA IgG; Vircell, Gra-
nada, Spain) was recently commercialized for C. albicans
germ tube-speciﬁc antibody (CAGTA) detection. The pres-
ent study aimed to determine the positive result rate of
CAGTA testing in critically-ill patients and to assess its diag-
nostic and prognostic usefulnesses in this setting.
A prospective observational multicentre study was con-
ducted at six Spanish University hospitals over a 2-year per-
iod (2005 to 2006). Inclusion criteria were: (i) acute
pancreatitis of >7 days of disease evolution; (ii) prolonged
intensive care unit (ICU) stay (>14 days) in conjunction with
‡3 risk factors (e.g. diabetes mellitus, extra-renal depuration,
parenteral nutrition, >7 days of broad-spectrum antibiotic
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